Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astefania: Atezolizumab + Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer
NCT04873362Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of atezolizumab in breast cancer, sponsored by Roche. Started May 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04873362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873362.